Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance

At the World AMR Congress, Recce Pharmaceuticals contributes by making strides with a synthetic compound designed to target bacterial mutations, underscoring the need for innovation in addressing antimicrobial resistance (AMR). “Our compound is entirely synthetic,” Graham said. “We started with first principles, designing a compound that remains effective with repeated use.”

The new antibiotic functions as a broad-spectrum solution, targeting bacteria across various infections without distinguishing between ‘good’ and ‘bad’ bacteria. “Bacteria mutate continuously, but our compound remains effective regardless of these mutations. It functions as a broad-spectrum antibiotic, targeting bacteria across various infections, such as UTIs, without distinguishing between ‘good’ and ‘bad’ bacteria. This allows us to work faster and more effectively than other antibiotics. Our compound empowers clinicians to treat patients quickly and reliably, even with repeated use.”

Graham addressed current gaps in AMR awareness, noting that the industry often repeats existing strategies while expecting different results. “We have approached this challenge differently by exploring polymeric chemistry, creating a compound that remains effective and soluble across various pH levels, including those found in the blood and stomach. The industry must innovate rather than reiterate existing methods. The market recognizes and rewards genuine innovation that delivers substantial value.”

On market adoption, Graham highlighted the challenges of introducing novel treatments and strategies to bring new antimicrobial treatments to market to become broadly adopted. “Bringing anything new to market is challenging, especially with novel compounds. The more innovative a product, the more hesitant the industry can be.”

The development process includes identifying and patenting the optimal compound, navigating regulatory cycles from preclinical to clinical trials, and achieving real-world clinical outcomes.

Graham discusses the stages of product development:

• Identifying and patenting the optimal compound,
• Navigating the regulatory cycle from preclinical to clinical trials
• Achieving real-world clinical outcomes.

Successfully completing these stages drives investor and commercial interest. Reece Pharmaceuticals’ efforts significantly advance AMR treatment, aiming to provide effective solutions for critical infections.